Feedback
Settings

Settings

Goto Application

985,438 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 98,544
1.WO/2025/261607PARTICLES, COMPOSITIONS AND METHODS
WO - 26.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/EP2024/067468 Applicant BIONTECH SE Inventor THANKI, Kaushik
The present disclosure relates generally to nucleic acid-lipid particles, in particular functionalized nucleic acid-lipid particles, methods for producing them, to aqueous dispersions suitable for forming the nucleic acid-lipid particles and methods for producing them, and to pharmaceutical compositions containing them and their uses in medicine.
2.WO/2025/262162METHOD FOR DETERMINING EMPTY, PARTIALLY FILLED AND FULL RECOMBINANT AAV PARTICLES
WO - 26.12.2025
Int.Class G01N 15/10
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
15Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
10Investigating individual particles
 Appl.No PCT/EP2025/067157 Applicant F. HOFFMANN-LA ROCHE AG Inventor FRANKEN, Linda Elise
Herein is reported a method for determining the amount or/and ratio of filled recombinant virus particles, such as recombinant adeno-associated virus particles (rAAVps), compared to empty and partially filled viral particles in a sample using transmission electron microscopy (TEM) with an EM grid without chemical staining, wherein the method comprises the step of drying the sample, preferably air-drying the sample, on the EM grid.
3.WO/2025/263737COMPOSITION FOR PREVENTING OR TREATING NEMATODE DISEASES, COMPRISING DPY-13 AND CALU-1 INHIBITOR
WO - 26.12.2025
Int.Class A61K 31/713
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
 Appl.No PCT/KR2025/002676 Applicant WONKWANG UNIVERSITY CENTER FOR INDUSTRY-ACADEMY COOPERATION Inventor SONG, Hyun-Ok
The present invention relates to a composition for preventing or treating nematode diseases, the composition comprising a DPY-13 and CALU-1 inhibitor. The inhibitor according to the present invention modifies collagen and delays development in nematodes, and reduces the fertility of adults, thus having increased epidermal permeability and able to effectively increase drug delivery efficiency for nematode diseases. Accordingly, the present invention provides a use of the composition for treating nematode diseases, and thus can be effectively used in studies of not only filaricides but also control agents for various nematodes such as soil nematodes and pine wood nematodes.
4.WO/2025/264577INSECTICIDAL PROTEINS, COMPOSITIONS AND METHODS OF USE
WO - 26.12.2025
Int.Class C12N 15/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
 Appl.No PCT/US2025/033810 Applicant GENECTIVE SA Inventor HU, Yuanyuan
Disclosed herein are transformed plants, plant tissues, plant parts, plant cells, and plant seeds comprising a recombinant nucleic acid molecule encoding a polypeptide having insecticidal activity. Also disclosed herein are methods of protecting or treating a plant from infection by a plant pathogen or pest by transforming plants, plant tissues, plant parts, plant cells, and plant seeds with a recombinant nucleic acid molecule encoding a polypeptide having Seq. ID No. 1 and having insecticidal activity.
5.WO/2025/264937LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES
WO - 26.12.2025
Int.Class A61K 9/1272
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
1272comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
 Appl.No PCT/US2025/034395 Applicant AKAGERA MEDICINES, INC. Inventor DRUMMOND, Daryl C.
Aspects of the present disclosure provides for improved vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage.
6.WO/2025/264967AGENTS AND/OR COMPOSITIONS USEFUL FOR MODULATING CIS-REGULATORY ELEMENTS IN SYNUCLEINOPATHIES AND METHODS FOR IDENTIFYING AGENTS AND COMPOSITIONS THEREOF
WO - 26.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/034447 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor MCCALLION, Andrew S.
The present disclosure relates to methods of preventing, or delaying the progression of, death of neurons and/or microgliosis and/or astrogliosis that contributes to the death of neurons. The present disclosure also relates to methods of treating, preventing, or delaying the progression of, a synucleinopathy (e.g., Parkinson's disease). Also disclosed are related in vitro, ex vivo, and in vivo methods of identifying agents and/or compositions useful for preventing, or delaying the progression of, death of neurons and/or microgliosis and/or astrogliosis that contributes to the death of neurons and agents and/or compositions useful for treating, preventing, or delaying the progression of, a synucleinopathy. The agents and/or compositions of the present disclosure decrease the level and/or activity of a cis-regulatory element that propagates the misfolding and aggregation of proteins encoded by synucleinopathy-associated genes in neurons and/or glial cells.
7.WO/2025/264952NOVEL RNA THERAPEUTICS AND USES THEREOF
WO - 26.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/034422 Applicant ELI LILLY AND COMPANY Inventor BAWEL, Seth Andrew
The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder.
8.WO/2025/263467METHOD FOR PRODUCING ISOPROPANOL
WO - 26.12.2025
Int.Class C12P 7/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
7Preparation of oxygen-containing organic compounds
02containing a hydroxy group
04acyclic
 Appl.No PCT/JP2025/021607 Applicant SUMITOMO CHEMICAL COMPANY, LIMITED Inventor TAKAHASHI, Yu
The present invention relates to a method for producing isopropanol by using a recombinant microorganism derived from a hydrogen-oxidizing bacterium and also using carbon dioxide as a carbon source. The present invention provides a method for producing isopropanol from a carbon source, the method using a recombinant microorganism derived from a bacterium belonging to the genus Cupriavidus. The method comprises (1) a first step for culturing the recombinant microorganism derived from a bacterium belonging to the genus Cupriavidus until the expression level of an indicator biomolecule alters, and (2) a second step for producing isopropanol by culturing the recombinant microorganism derived from a bacterium belonging to the genus Cupriavidus, which is cultured in the first step, under conditions that the alteration of the indicator biomolecule is maintained, wherein the recombinant microorganism derived from a bacterium belonging to the genus Capryavidus has an acetoacetate decarboxylase gene and an alcohol dehydrogenase gene introduced thereto.
9.WO/2025/264727COMPOSITIONS AND METHODS OF SLC7A1 AND SLC7A2
WO - 26.12.2025
Int.Class A61K 31/7084
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
 Appl.No PCT/US2025/034053 Applicant ARC RESEARCH INSTITUTE Inventor LI, Lingyin
Compositions and methods for reducing toxicity in T cells, among other inventions, are provided.
10.WO/2025/262672LIPID COMPOSITIONS FOR NUCLEIC ACID DELIVERY
WO - 26.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/IB2025/056321 Applicant BIONTECH SE Inventor PANZNER, Steffen
The present disclosure provides, among other things, composition and uses of said compositions comprising a cationic lipid, an anionically ionizable lipid, and a nucleic acid, wherein: the cationic lipid comprises a cationic head group, a first bridge group, and a first lipid tail group; the anionically ionizable lipid comprises an anionically ionizable head group, a second bridge group, and a second lipid tail group; the cationic lipid has a lipidic volume from about 700 Å3 to about 1500 Å3, and/or the anionically ionizable lipid has a lipidic volume from about 700 Å3 to about 1500 Å3; or the cationic lipid and the anionically ionizable lipid have a combined lipidic volume greater than 1400 Å3. In some embodiments, the present disclosure provides new cationic lipids and new anionically ionizable lipids.
# -